Large meta-analyses and pooled data from randomized controlled trials demonstrate that GLP-1 receptor agonists do not increase the risk of depression, anxiety, suicidality, or other serious psychiatric adverse events compared to placebo
A treatment-related increase in malignant thyroid C-cell carcinomas was observed in all male liraglutide-treated groups with incidences of 2%, 8%, 6%, and 14% and in females at 0.25 and 0.75 mg/kg/day with incidences of 0%, 0%, 4%, and 6% in 0 (control), 0.075, 0.25, and 0.75 mg/kg/day groups, respectively
It summarizes the major risks, frequent side effects, and primary contraindications
At this time, limited published data confirm that GLP-1 patches work at therapeutic levels comparable to injectable formulations